ImmuneOnco signed licensing and CMO service agreements with Wo-Yun Investment LLP and Genor Biopharma (Yuxi, Yunnan, June 8, 2016)

ImmuneOnco secures 5 million RMB in the second round of pre-A round fund-raising from Shanghai Zhangjiang Science & Technology Venture Capital Co., Ltd (ZJSTVC).

ImmuneOnco secures 5 million RMB in the second round of pre-A round fund-raising from Shanghai Zhangjiang Science & Technology Venture Capital Co., Ltd (ZJSTVC).

ImmuneOnco announces acceptance of patent application by China SIPO on a novel recombinant chimeric PD-1 receptor (CPR)

On January 14 of 2016, ImmuneOnco announced acceptance of the patent application on a novel engineered recombinant chimeric PD-1 receptor (CPR).

ImmuneOnco announces successful development of FcR-TANK cell line that will be used in combination with antibody for treatment of patients with cancer

ImmuneOnco Biopharma Co., Ltd, an early-stage immunotherapy company dedicated to development and commercialization of novel cancer immunotherapy products,

ImmuneOnco secures 25 million RMB in pre-A round of fund-raising from Shanghai Zhangke Lingyi Investment Corporation

ImmuneOnco Biopharma Co., Ltd today announced closing of first round fund-raising in pre-A round as of the amount of 25 million RMB

ImmuneOnco announces acceptance of PCT application by China PCT-SAFE on a novel recombinant bi-functional protein licensed from third party

On November 16 of 2015, we have successfully confirmed acceptance of the application of PCT (PCT/CN2015/094739) on a novel engineered recombinant protein with two specific biological...

ImmuneOnco announces filing of trademark registration of “X-TANK™”

On November 12 of 2015, we have successfully filed the application of trademark registration on “X-TANK”, in which “X” represents any disease target, “TANK” stands for “Target-Activa...

ImmuneOnco was incorporated in June of 2015

ImmuneOnco Biopharmaceuticals Co., Ltd was incorporated in June of 2015 in Free Trade Zone of Shanghai, China.